Randomized Trialhigh evidence

Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.

JAMA neurology·November 9, 2026·PMID 43002431

Why it matters

Despite many available antiseizure medications, a substantial proportion of patients with focal epilepsy remain drug-resistant. Azetukalner's novel mechanism and robust efficacy in this trial suggest a potential new option for reducing seizure burden in this challenging population.

Infographic summary of Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled